After VEGFR-TKI failure in aRCC,
AFINITOR more than doubled median PFS as compared with placebo1
As shown in a post-hoc subanalysis of RECORD-1,
AFINITOR demonstrated efficacy after either 1 or 2 VEGFR-TKIs2
†Median PFS in patients who received only 1 prior VEGFR-TKI and median PFS in patients who received 2 prior VEGFR-TKIs by treatment arm in a post-hoc subanalysis of RECORD-1. These data are not a part of the AFINITOR Summary of Product Characteristics.1
aRCC, advanced renal cell carcinoma; PFS, progression-free survival; VEGFR-TKI, vascular endothelial growth factor receptor-tyrosine kinase inhibitor.
- AFINITOR [summary of product characteristics]. Novartis Pharma AG; 2017.
- Calvo E, Escudier B, Motzer RJ, et al. Everolimus in metastatic renal cell carcinoma: subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer. 2012;48(3):333-339.